跳至主要内容
临床试验/NCT02712463
NCT02712463已完成不适用

A Retrospective, Observational Study to Assess the Rate of Hospitalization in Patients With Schizophrenia Treated One Year Before With Oral Antipsychotics and One Year After With Long Acting Injectable Atypical Antipsychotics - REALAI Study

Janssen-Cilag Ltd.0 个研究点目标入组 310 人开始时间: 2015年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
310
主要终点
Percentage of Participants with Hospitalizations in 12 Months Before Initial Long Acting Injectable anti-psychotics (LAI) use

研究概览

简要总结

The primary purpose of the study is to compare the rate of hospitalization associated with psychotic relapse in participants with schizophrenia treated one year before with oral antipsychotics and one year after with long acting injectable atypical antipsychotics.

详细描述

This is a retrospective (take a look back at events that already have taken place), observational, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adults with a diagnosis of Schizophrenia during the time period from 01 January 2009 through 31-December-2013 (only for Mexican population). Data will be collected from clinical practice. The medical records of participants will be screened and eligible participants data will be collected. The period of observation will span from 12 months before initial Long Acting Injectable (LAI) use and in 12 months after the initial LAIs use. The rate of hospitalization will be primarily evaluated.

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Out-Patients with the main diagnosis of schizophrenia with Diagnostic and Statistical Manual of Mental Disorders (DSM-4 criteria)
  • Only clinical records with complete information during the 2 years period selected for data analysis will be included
  • Participants treated with oral antipsychotics then switched to Long Acting Injectable (LAI) due to poor adherence, lack of efficacy (no significant symptom reduction, judged by physician, at maximum recommended dose of an antipsychotic for 6 weeks), or participants choice, (Excluding for the Brazil population, when the switch has not been clearly justified or the switch has not been done during hospitalization)
  • Being regularly treated with LAI atypical antipsychotics for at least 1 year after the initial use of LAI atypical antipsychotics

排除标准

  • Participants with refractory schizophrenia (RS)
  • Participants that started LAI treatment as in-patients and patients that switched to LAI during hospitalization (only for Mexican population).

结局指标

主要结局

Percentage of Participants with Hospitalizations in 12 Months Before Initial Long Acting Injectable anti-psychotics (LAI) use

时间窗: 12 months before initial LAI use

Percentage of participants with hospitalizations due to Psychotic relapse of schizophrenia will be reported.

Percentage of Participants with Hospitalizations in 12 Months After Initial Long Acting Injectable anti-psychotics (LAI) use

时间窗: 12 months after initial LAI use

次要结局

  • Number of Days of Hospitalization due to Psychotic Relapse of Schizophrenia(approximately 2 years)
  • Number of hospitalizations due to Psychotic Relapse of Schizophrenia(approximately 2 years)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验